It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HYPMY’s FA Score shows that 1 FA rating(s) are green whileIPSEY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HYPMY’s TA Score shows that 5 TA indicator(s) are bullish while IPSEY’s TA Score has 4 bullish TA indicator(s).
HYPMY (@Pharmaceuticals: Other) experienced а -17.19% price change this week, while IPSEY (@Pharmaceuticals: Other) price change was -2.59% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.75%. For the same industry, the average monthly price growth was +1.64%, and the average quarterly price growth was -9.20%.
IPSEY is expected to report earnings on Feb 13, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
HYPMY | IPSEY | HYPMY / IPSEY | |
Capitalization | 5.79B | 10.4B | 56% |
EBITDA | 2.86B | 889M | 321% |
Gain YTD | -58.619 | -2.277 | 2,574% |
P/E Ratio | 15.95 | 23.47 | 68% |
Revenue | 7.75B | 3.28B | 236% |
Total Cash | N/A | 438M | - |
Total Debt | N/A | 1.2M | - |
HYPMY | IPSEY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 32 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 59 | 76 | |
PRICE GROWTH RATING 1..100 | 92 | 59 | |
P/E GROWTH RATING 1..100 | 92 | 69 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HYPMY's Valuation (3) in the null industry is in the same range as IPSEY (32). This means that HYPMY’s stock grew similarly to IPSEY’s over the last 12 months.
IPSEY's Profit vs Risk Rating (77) in the null industry is in the same range as HYPMY (100). This means that IPSEY’s stock grew similarly to HYPMY’s over the last 12 months.
HYPMY's SMR Rating (59) in the null industry is in the same range as IPSEY (76). This means that HYPMY’s stock grew similarly to IPSEY’s over the last 12 months.
IPSEY's Price Growth Rating (59) in the null industry is somewhat better than the same rating for HYPMY (92). This means that IPSEY’s stock grew somewhat faster than HYPMY’s over the last 12 months.
IPSEY's P/E Growth Rating (69) in the null industry is in the same range as HYPMY (92). This means that IPSEY’s stock grew similarly to HYPMY’s over the last 12 months.
HYPMY | IPSEY | |
---|---|---|
RSI ODDS (%) | 2 days ago68% | 2 days ago80% |
Stochastic ODDS (%) | 2 days ago65% | 2 days ago61% |
Momentum ODDS (%) | N/A | 2 days ago47% |
MACD ODDS (%) | 2 days ago70% | 2 days ago65% |
TrendWeek ODDS (%) | 2 days ago76% | 2 days ago54% |
TrendMonth ODDS (%) | 2 days ago79% | 2 days ago55% |
Advances ODDS (%) | 8 days ago65% | N/A |
Declines ODDS (%) | 3 days ago75% | 10 days ago49% |
BollingerBands ODDS (%) | 2 days ago68% | 2 days ago76% |
Aroon ODDS (%) | 2 days ago76% | 2 days ago54% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GREIX | 12.40 | N/A | N/A |
Goldman Sachs Real Estate Securities Ins | |||
RSERX | 20.33 | N/A | N/A |
Victory Sophus Emerging Markets R6 | |||
NIQAX | 13.51 | N/A | N/A |
Neuberger Berman International Eq A | |||
PABGX | 187.06 | -0.45 | -0.24% |
T. Rowe Price Blue Chip Growth Advisor | |||
FVDFX | 37.11 | -0.22 | -0.59% |
Fidelity Value Discovery |
A.I.dvisor tells us that HYPMY and AYRWF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HYPMY and AYRWF's prices will move in lockstep.
Ticker / NAME | Correlation To HYPMY | 1D Price Change % | ||
---|---|---|---|---|
HYPMY | 100% | +0.02% | ||
AYRWF - HYPMY | 23% Poorly correlated | +17.72% | ||
PLNH - HYPMY | 21% Poorly correlated | +2.33% | ||
CPIX - HYPMY | 20% Poorly correlated | N/A | ||
GLASF - HYPMY | 20% Poorly correlated | -1.99% | ||
KMDA - HYPMY | 20% Poorly correlated | -0.86% | ||
More |
A.I.dvisor tells us that IPSEY and LBTSF have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPSEY and LBTSF's prices will move in lockstep.
Ticker / NAME | Correlation To IPSEY | 1D Price Change % | ||
---|---|---|---|---|
IPSEY | 100% | -1.49% | ||
LBTSF - IPSEY | 15% Poorly correlated | N/A | ||
LVRLF - IPSEY | 9% Poorly correlated | +4.55% | ||
HYPMY - IPSEY | 7% Poorly correlated | +0.02% | ||
IPSEF - IPSEY | 6% Poorly correlated | N/A | ||
INDV - IPSEY | 5% Poorly correlated | -1.90% | ||
More |